Literature DB >> 6141198

The pharmacokinetics and antihistaminic of the H1 receptor antagonist hydroxyzine.

F E Simons, K J Simons, E M Frith.   

Abstract

We studied the pharmacokinetics and the suppression of histamine-induced wheals, flares, and pruritus in the skin after administration of the histamine H1 antagonist hydroxyzine to seven healthy adults. After a single oral dose of hydroxyzine, 0.7 mg/kg (mean dose 39.0 +/- 5.4 mg), the mean maximum serum hydroxyzine concentration of 72.5 +/- 11.1 ng/ml occurred at a mean time of 2.1 +/- 0.4 hr. The mean elimination half-life calculated from the terminal linear portion of the serum hydroxyzine concentration vs. time curve was 20.0 +/- 4.1 hr. The mean clearance rate was 9.78 +/- 3.25 ml/min/kg and the mean volume of distribution was 16.0 +/- 3.0 L/kg. The single dose of hydroxyzine suppressed pruritus at the wheal and flare sites from 1 to 36 hr. Maximal suppression of the wheals was 80% and maximal suppression of the flares was 92%. Significant suppression of the wheals and flares persisted for 36 and 60 hr, respectively. Pharmacodynamic analysis of the wheal and flare suppression data and the mean serum hydroxyzine concentrations supports the prolonged terminal serum half-life value for the drug.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6141198     DOI: 10.1016/0091-6749(84)90486-x

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  14 in total

Review 1.  Pharmacokinetic optimisation of histamine H1-receptor antagonist therapy.

Authors:  F E Simons; K J Simons
Journal:  Clin Pharmacokinet       Date:  1991-11       Impact factor: 6.447

2.  Effect of the H2-receptor antagonist cimetidine, on the pharmacokinetics and pharmacodynamics of the H1-receptor antagonists hydroxyzine and cetirizine in rabbits.

Authors:  X Chen; F E Simons; K J Simons
Journal:  Pharm Res       Date:  1994-02       Impact factor: 4.200

Review 3.  Optimum pharmacological management of chronic rhinitis.

Authors:  F E Simons; K J Simons
Journal:  Drugs       Date:  1989-08       Impact factor: 9.546

Review 4.  Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions.

Authors:  R J Bertz; G R Granneman
Journal:  Clin Pharmacokinet       Date:  1997-03       Impact factor: 6.447

Review 5.  Clinical pharmacokinetics of H1-receptor antagonists (the antihistamines).

Authors:  D M Paton; D R Webster
Journal:  Clin Pharmacokinet       Date:  1985 Nov-Dec       Impact factor: 6.447

6.  Hydroxyzine from topical phospholipid liposomal formulations: evaluation of peripheral antihistaminic activity and systemic absorption in a rabbit model.

Authors:  Abeer A W Elzainy; Xiaochen Gu; F Estelle R Simons; Keith J Simons
Journal:  AAPS PharmSci       Date:  2003-11-05

Review 7.  Pharmacologic treatment of rhinitis.

Authors:  F E Simons; K J Simons
Journal:  Clin Rev Allergy       Date:  1984-08

Review 8.  H1-receptor antagonists. Comparative tolerability and safety.

Authors:  F E Simons
Journal:  Drug Saf       Date:  1994-05       Impact factor: 5.606

9.  Selective inhibition of hepatitis C virus infection by hydroxyzine and benztropine.

Authors:  Lidia Mingorance; Martina Friesland; Mairene Coto-Llerena; Sofía Pérez-del-Pulgar; Loreto Boix; Juan Manuel López-Oliva; Jordi Bruix; Xavier Forns; Pablo Gastaminza
Journal:  Antimicrob Agents Chemother       Date:  2014-04-07       Impact factor: 5.191

10.  Semiparametric analysis of non-steady-state pharmacodynamic data.

Authors:  D Verotta; L B Sheiner
Journal:  J Pharmacokinet Biopharm       Date:  1991-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.